Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Performance of [⁶⁸Ga]Ga-DLL3 Nanobody PET/CT in Metastatic Neuroendocrine Neoplasms
NCT07733024Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-PFD3 in Neuroendocrine Neoplasm (NEN). Started Jul 2026; status: recruiting.
02
Drugs
68Ga-PFD3
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT07733024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733024.